Follicular Lymphoma Latest Advances

Pneumocystis jirovecii infection in autologous hematopoietic stem cell transplantation.

Journal: Leukemia & lymphoma

Published: January 23, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.

Journal: International journal of clinical oncology

Published: January 08, 2026

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Journal: Immuno-oncology technology

Published: January 08, 2026

Casulo C, Dixon JG, Ou F-S, et al. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Adv. 2021;5(6):1737-1745.

Journal: Blood advances

Published: January 06, 2026

Epcoritimab Combo Could Be New Standard for Some FLs.

Journal: Cancer discovery

Published: January 05, 2026

Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5.

Journal: Leukemia & lymphoma

Published: December 30, 2025

Highlights: Immunotherapy for B-cell lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: December 24, 2025

Chimeric antigen receptor T-cell and bispecific antibody therapies for follicular lymphoma: Recent advances and future prospects.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: December 24, 2025

A novel case of presumed immunotherapy related inflammatory orbitopathy.

Journal: Orbit (Amsterdam, Netherlands)

Published: December 23, 2025

Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 22, 2025

Post-Marketing Safety of Tazemetostat in Antitumor Therapy: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

Journal: Cancer investigation

Published: December 19, 2025

Therapy of follicular lymphoma associated bronchiolitis obliterans with lung transplantation: 2 cases and literature review

Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Published: December 09, 2025